HRP20171889T1 - Formulacije kombinacije darunavira - Google Patents
Formulacije kombinacije darunaviraInfo
- Publication number
- HRP20171889T1 HRP20171889T1 HRP20171889TT HRP20171889T HRP20171889T1 HR P20171889 T1 HRP20171889 T1 HR P20171889T1 HR P20171889T T HRP20171889T T HR P20171889TT HR P20171889 T HRP20171889 T HR P20171889T HR P20171889 T1 HRP20171889 T1 HR P20171889T1
- Authority
- HR
- Croatia
- Prior art keywords
- darunavir
- combination formulations
- formulations
- combination
- darunavir combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Inorganic Chemistry (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Oncology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11173067 | 2011-07-07 | ||
| PCT/EP2012/063249 WO2013004818A1 (en) | 2011-07-07 | 2012-07-06 | Darunavir combination formulations |
| EP12738060.8A EP2729130B1 (en) | 2011-07-07 | 2012-07-06 | Darunavir combination formulations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20171889T1 true HRP20171889T1 (hr) | 2018-01-12 |
Family
ID=46551505
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20171889TT HRP20171889T1 (hr) | 2011-07-07 | 2012-07-06 | Formulacije kombinacije darunavira |
Country Status (24)
| Country | Link |
|---|---|
| US (3) | US20140142070A1 (enExample) |
| EP (1) | EP2729130B1 (enExample) |
| JP (1) | JP6122427B2 (enExample) |
| KR (1) | KR102058097B1 (enExample) |
| CN (1) | CN103826616B (enExample) |
| AU (1) | AU2012280198B2 (enExample) |
| BR (1) | BR112014000290B1 (enExample) |
| CA (1) | CA2838659C (enExample) |
| CY (1) | CY1121999T1 (enExample) |
| DK (1) | DK2729130T3 (enExample) |
| EA (1) | EA026587B1 (enExample) |
| ES (1) | ES2651212T3 (enExample) |
| HR (1) | HRP20171889T1 (enExample) |
| HU (1) | HUE035241T2 (enExample) |
| IL (1) | IL229933A (enExample) |
| LT (1) | LT2729130T (enExample) |
| MX (1) | MX343689B (enExample) |
| NO (1) | NO2729130T3 (enExample) |
| PL (1) | PL2729130T3 (enExample) |
| PT (1) | PT2729130T (enExample) |
| RS (1) | RS56667B1 (enExample) |
| SI (1) | SI2729130T1 (enExample) |
| SM (1) | SMT201700574T1 (enExample) |
| WO (1) | WO2013004818A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012280198B2 (en) | 2011-07-07 | 2016-12-22 | Gilead Sciences, Inc. | Darunavir combination formulations |
| JP2015508822A (ja) * | 2012-03-01 | 2015-03-23 | ギリアード サイエンシーズ， インコーポレイテッド | 噴霧乾燥製剤 |
| DK2822954T3 (en) | 2012-12-21 | 2016-05-30 | Gilead Sciences Inc | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE |
| BR102016026127A2 (pt) | 2015-11-09 | 2017-05-16 | Gilead Sciences Inc | composições terapêuticas para o tratamento do vírus da imunodeficiência humana |
| EP3496710A4 (en) * | 2016-08-08 | 2020-03-18 | Hetero Labs Limited | TABLET COMPOSITION WITH A HIGH ACTIVE SUBSTANCE LOAD FOR TREATING HIV |
| EP3496718A4 (en) | 2016-08-08 | 2020-01-22 | Hetero Labs Limited | ANTIRETROVIRAL COMPOSITIONS |
| BR112019002120A2 (pt) * | 2016-08-08 | 2019-05-14 | Hetero Labs Limited | composição anti-retroviral de várias classes |
| US20180085387A1 (en) * | 2016-09-27 | 2018-03-29 | Gilead Sciences, Inc. | Therapeutic compositions for treatment of human immunodeficiency virus |
| WO2019018676A1 (en) | 2017-07-20 | 2019-01-24 | Janssen Sciences Ireland Unlimited Company | COMPOSITIONS COMPRISING DARUNAVIR, COBICISTAT, EMTRICITABINE AND TENOFOVIR ALAFENAMIDE FOR USE IN THE TREATMENT OF HIV |
| US20200101093A1 (en) | 2018-09-28 | 2020-04-02 | Janssen Sciences Ireland Unlimited Company | Methods of Treating and Preventing Neuropsychiatric and/or Neurocognitive Complications in Patients Infected with HIV |
| US20210290590A1 (en) | 2020-03-13 | 2021-09-23 | Janssen Sciences Ireland Unlimited Company | Methods of treating subjects infected with hiv |
| CN119700779B (zh) * | 2024-11-28 | 2025-11-04 | 安徽贝克生物制药有限公司 | 一种达芦那韦和考比司他复合片剂及其制备方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5968942A (en) | 1992-08-25 | 1999-10-19 | G. D. Searle & Co. | α- and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| WO1995006030A1 (en) | 1993-08-24 | 1995-03-02 | G.D. Searle & Co. | Hydroxyethylamino sulphonamides useful as retroviral protease inhibitors |
| JP4776775B2 (ja) | 1998-06-23 | 2011-09-21 | アメリカ合衆国 | Ｈｉｖ感染哺乳動物を治療するための医薬組成物 |
| AR037797A1 (es) | 2001-12-12 | 2004-12-01 | Tibotec Pharm Ltd | Combinacion de inhibidores de proteasa dependientes del citocromo p450 |
| BRPI0311176B8 (pt) | 2002-05-16 | 2021-05-25 | Janssen Sciences Ireland Uc | pseudopolimorfo na forma de etanolato, seu uso, processo de preparação do mesmo e composição farmacêutica |
| TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
| EP2032536B1 (en) | 2006-05-30 | 2015-05-06 | Janssen Pharmaceutica N.V. | Substituted pyridyl amide compounds as modulators of the histamine h3 receptor |
| US20080039428A1 (en) * | 2006-06-29 | 2008-02-14 | Panacos Pharmaceuticals, Inc. | Antiretroviral combination therapy |
| AR061838A1 (es) | 2006-07-07 | 2008-09-24 | Gilead Sciences Inc | Moduladores de propiedades farmacocineticas de terapeuticos |
| US20080113021A1 (en) * | 2006-10-25 | 2008-05-15 | Robert Shen | Ibuprofen composition |
| ES2779826T3 (es) | 2007-02-23 | 2020-08-20 | Gilead Sciences Inc | Moduladores de propiedades farmacocinéticas de agentes terapéuticos |
| JP2010531301A (ja) * | 2007-06-25 | 2010-09-24 | テイボテク・フアーマシユーチカルズ | ダルナビル及びエトラビリンを含んでなる組み合わせ調剤 |
| AR069539A1 (es) | 2007-07-25 | 2010-02-03 | Tibotec Pharm Ltd | Avances respecto de las formulaciones de comprimidos contra el vih |
| CN101868454A (zh) | 2007-11-20 | 2010-10-20 | 詹森药业有限公司 | 作为组胺h3受体调节剂的环烷基氧基吡啶化合物和杂环烷基氧基吡啶化合物 |
| GT200800303A (es) * | 2007-12-24 | 2009-09-18 | Combinacion anti-retroviral | |
| PT2296633E (pt) | 2008-05-02 | 2015-12-04 | Gilead Sciences Inc | A utilização de partículas de portador sólido para melhorar a processabilidade de um agente farmacêutico |
| CN102307573B (zh) * | 2009-02-06 | 2013-09-11 | 吉里德科学公司 | 用于联合治疗的片剂 |
| HRP20170392T1 (hr) * | 2009-09-17 | 2017-06-02 | Mylan Laboratories Limited | Postupak za pripremu darunavira i njegovog amorfnog oblika |
| EP2568810B1 (en) | 2010-05-10 | 2018-09-19 | Hetero Research Foundation | Darunavir compositions |
| RS55236B1 (sr) | 2011-07-07 | 2017-02-28 | Janssen Sciences Ireland Uc | Formulacije leka darunavir |
| AU2012280198B2 (en) | 2011-07-07 | 2016-12-22 | Gilead Sciences, Inc. | Darunavir combination formulations |
| WO2013115916A1 (en) | 2012-02-03 | 2013-08-08 | Gilead Sciences, Inc. | Combination therapy comprising gs-7340 and cobicistat for use in the treatment of viral infections |
| AU2015373104B2 (en) | 2015-01-03 | 2020-07-09 | Mylan Laboratories Limited | Processes for the preparation of amorphous tenofovir alafenamide hemifumarate and a premix thereof |
-
2012
- 2012-07-06 AU AU2012280198A patent/AU2012280198B2/en active Active
- 2012-07-06 PL PL12738060T patent/PL2729130T3/pl unknown
- 2012-07-06 BR BR112014000290-8A patent/BR112014000290B1/pt active IP Right Grant
- 2012-07-06 RS RS20171244A patent/RS56667B1/sr unknown
- 2012-07-06 LT LTEP12738060.8T patent/LT2729130T/lt unknown
- 2012-07-06 JP JP2014517822A patent/JP6122427B2/ja active Active
- 2012-07-06 EP EP12738060.8A patent/EP2729130B1/en active Active
- 2012-07-06 SI SI201231141T patent/SI2729130T1/en unknown
- 2012-07-06 NO NO12738060A patent/NO2729130T3/no unknown
- 2012-07-06 CA CA2838659A patent/CA2838659C/en active Active
- 2012-07-06 MX MX2013015199A patent/MX343689B/es active IP Right Grant
- 2012-07-06 KR KR1020147000092A patent/KR102058097B1/ko active Active
- 2012-07-06 HU HUE12738060A patent/HUE035241T2/en unknown
- 2012-07-06 EA EA201490222A patent/EA026587B1/ru unknown
- 2012-07-06 HR HRP20171889TT patent/HRP20171889T1/hr unknown
- 2012-07-06 CN CN201280033554.0A patent/CN103826616B/zh active Active
- 2012-07-06 PT PT127380608T patent/PT2729130T/pt unknown
- 2012-07-06 ES ES12738060.8T patent/ES2651212T3/es active Active
- 2012-07-06 SM SM20170574T patent/SMT201700574T1/it unknown
- 2012-07-06 DK DK12738060.8T patent/DK2729130T3/en active
- 2012-07-06 WO PCT/EP2012/063249 patent/WO2013004818A1/en not_active Ceased
- 2012-07-06 US US14/131,282 patent/US20140142070A1/en not_active Abandoned
-
2013
- 2013-12-17 IL IL229933A patent/IL229933A/en active IP Right Grant
-
2017
- 2017-12-05 CY CY20171101267T patent/CY1121999T1/el unknown
-
2019
- 2019-11-27 US US16/697,888 patent/US11654150B2/en active Active
-
2023
- 2023-05-05 US US18/313,266 patent/US20230302024A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3725778T1 (sl) | Formulacije enzalutamida | |
| DK3117837T3 (da) | Antistofformuleringer | |
| EP2747556A4 (en) | pyrethroid formulations | |
| CO6801645A2 (es) | Nuevos inmunoconjugados | |
| DK3091029T5 (da) | Anti-IL13-antistofformuleringer | |
| HRP20181615T1 (hr) | Terapijsko sredstvo koje izaziva citotoksičnost | |
| DK3620175T3 (da) | Højkoncentrerede antistofformuleringer | |
| BR112013017183A2 (pt) | composições de bepostatina | |
| CO6801637A2 (es) | Formulaciones de anticuerpos | |
| HRP20160887T1 (hr) | Formulacije testosterona | |
| HRP20171889T1 (hr) | Formulacije kombinacije darunavira | |
| SMT201700110B (it) | Composizione immunogena | |
| CO6940426A2 (es) | Formulaciones farmacéuticas | |
| EP2552212A4 (en) | IMPROVED FORMULATION | |
| CO6761402A2 (es) | Formulaciones inmunosupresoras | |
| BR112014000015A2 (pt) | formulação | |
| EP2531023A4 (en) | IMPROVED FORMULATION | |
| SMT201600380B (it) | Formulazioni di darunavir | |
| EP2769718A4 (en) | MEDICAL COMPOSITION | |
| IL231660A0 (en) | Composition | |
| PT2908835T (pt) | Formulações estáveis | |
| DK2931042T3 (da) | Anthracyclinformuleringer | |
| IL228573A0 (en) | Otamixaban formulations with improved stability | |
| EP2770828A4 (en) | FORMULATION | |
| DK2672817T3 (da) | Forbedrede insekticide formuleringer |